Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Update

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 114,388 shares, a decline of 71.6% from the August 31st total of 403,209 shares. Based on an average daily trading volume, of 95,127 shares, the short-interest ratio is currently 1.2 days. Currently, 5.0% of the shares of the company are sold short.

Kairos Pharma Price Performance

Shares of NYSEAMERICAN:KAPA traded down $0.05 during trading on Friday, reaching $1.72. 42,261 shares of the company’s stock traded hands, compared to its average volume of 99,201. The stock has a market capitalization of $5.83 million, a P/E ratio of -0.88 and a beta of 1.48. Kairos Pharma has a 12 month low of $1.51 and a 12 month high of $9.59. The company has a 50 day moving average of $2.01 and a 200-day moving average of $3.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter. Equities research analysts predict that Kairos Pharma will post -2.59 earnings per share for the current fiscal year.

Kairos Pharma Company Profile

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on immuno-oncology, with an emphasis on addressing mechanisms that can cause tumors to resist existing treatments.

Kairos Pharma’s lead program, KPA-1102, is an investigational antibody designed to inhibit leukemia inhibitory factor (LIF), a signaling protein associated with tumor growth and immune suppression. The company is evaluating the potential use of this approach in combination with other cancer therapies, including immune checkpoint inhibitors.

The company is based in the United States and is focused primarily on advancing its drug candidates through clinical development and regulatory processes.